Proprietary Technologies: Enabling Greater Diagnostic Accuracy

Our Technology Supports Diagnostic Accuracy

Precipio has developed several cutting-edge technologies to support our unparalleled diagnostic accuracy in hematopathology. These technologies help address issues from low cellularity, false negatives in cytogenetics, and slow TAT’s for molecular testing.

We developed these technologies to address market challenges for clinical diagnostic accuracy, while preserving, and in many cases, improving turn around times. Connect with us to learn more about how we develop and employ these technologies in our clinical lab.  

Proprietary Molecular Panels

Our molecular panels were developed to solve common industry challenges through simplified workflows, resulting in faster turnaround times while providing more comprehensive diagnostic information for clinician to make more informed decisions. These panels are designed based on the latest NCCN guidelines for molecular testing of various blood cancers including MPN, CML (BCR-ABL1 and ABL1 Resistance), CLL, AML, and MDS. 

IV-Cell^TM

IV-Cell cytogenetics culture media was developed to reduce the chance of false negatives in cytogenetic testing. IV-Cell enables simultaneous culturing of all four hematopoietic cell lineages to solve this problem of selective culturing. This also enables faster turnaround times and safeguards against false negatives when improper culture conditions may be selected due to inaccurate initial clinical suspicions.

Rev-CI

Rev-CI was developed to address the complications of other commercial cell enrichment technologies that can hinder diagnostic accuracy. The Rev-CI proprietary procedure selectively enriches samples for cells of interest enabling conclusive FISH results for up to 98% of samples. This allows sub-classification of B-Cell lymphomas and definitive prognosis of Multiple Myelomas.